# The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer

> **NCT04411537** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 50 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer

## Interventions

- **DRUG:** PD-1 antibody
- **DRUG:** Capecitabine
- **DRUG:** Irinotecan
- **RADIATION:** Neoadjuvant Radiotherapy

## Key facts

- **NCT ID:** NCT04411537
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-01
- **Primary completion:** 2022-04-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04411537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04411537, "The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04411537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*